Calibra Dx Completes Tens of Millions of RMB Series C+ Financing to Accelerate Clinical Product Innovation

Recently, Hangzhou Calibra Precision Medical Testing Technology Co., Ltd. (hereinafter referred to as “Calibra”) announced the completion of its C+ round of financing, amounting to tens of millions of yuan. This round of financing was participated in by the biological and health investment platform under Chongqing Yufu Capital. This isCalibra completed its second round of financing in 2022, following its Series C funding.The proceeds from this round of financing will be primarily used to accelerate the market launch of self-developed innovative products.

Since its establishment in 2017, Calipso has adhered to the principle of “Achieving Healthy Living Through Innovative Diagnostics” mission, adhering to innovative mass spectrometry applications as the core technology, committed toMulti-Omics Data-Driven Product Innovation Strategy, continuously promoting ChinaClinical Translation and Standardization of Mass Spectrometry and Multi-OmicsOver the past five years since its establishment, the company has secured continuous investment from industry-leading enterprises and renowned funds, and has been listed on multiple prestigious rankings, including “Hangzhou Quasi-Unicorn Enterprises,” “Hangzhou Key Pre-IPO Enterprises,” and “KPMG China Biotech Innovation 50.”

In 2022, the companyAchieved key progress and breakthroughs across multiple business areas. The domestically produced clinical mass spectrometry detection system CalQuant-SApproved for market launch in March, the high-end mass spectrometry instruments have achieved localization and clinical application, with successful installation completed at dozens of domestic Grade A tertiary medical institutions within the year. The company’s subsidiary, Disaisi Diagnostics, independently developed and manufacturedCombined Assay of Five Steroid Hormones, Aldosterone and Cortisol, Therapeutic Drug Monitoring of Antiepileptic Drugs, Urinary Vanillylmandelic Acid and Creatinine, Fat-Soluble VitaminsMultiple Class II reagent products have continued to receive approval for market launch, including several first-in-China innovations, providing healthcare institutions with more reliable and diverse standardized product options for establishing clinical mass spectrometry platforms. The company’s independently developed CalOmics multi-omics platform, within the yearSuccessfully Completed a Cohort Study Project with a Sample Size of Over 10,000 Participants, the company's academic team supports partners as co-authors or project undertakers inPublished nearly 30 papers in high-impact academic journals, including *Nature Aging*, *Cell Discovery*, *Gastroenterology*, and the *Chinese Journal of Laboratory Medicine*., participated in drafting《Guidelines for the Detection of 25-Hydroxyvitamin D by Liquid Chromatography-Tandem Mass Spectrometry in Medical Laboratories》Group standards are continuously driving the translation of multi-omics from research tools to clinical value, as well as the ongoing implementation of industry standardization for clinical mass spectrometry in China.

Moving forward, Caliper will continue to increase its investments in R&D and marketing, with a particular focus on accelerating the development and regulatory approval of multi-omics translational innovative products. The company will also prioritize enhancing its customer experience-oriented service system, creating value for end users through integrated multi-omics clinical mass spectrometry solutions for precision diagnosis and treatment.

Ms. Liu Huafen, Chairwoman of Caliperstated, “We extend our gratitude to both new and existing investors for their recognition and support, which will inspire us to keep moving forward. Over the past year, we have launched a portfolio of clinical mass spectrometry products for the Chinese market, including high-end clinical mass spectrometry instruments, a range of clinical mass spectrometry assay kits covering nutrition, precision medication, and endocrinology, as well as comprehensive solutions that enable clinical users to achieve the full spectrum from multi-omics biomarker discovery to product translation and final clinical application. Since its inception, Calibra Biosciences has adhered to the principle of ‘adding’ technological innovation to ‘subtract’ human disease. This has been our original aspiration in founding the company, and we remain committed to it, continuously creating value for our users through our dedication and hard work.”

Cheng Hong, Head of the Biopharma and Health Investment Platform under Chongqing Yufu"Mass spectrometry testing represents another significant methodological advancement in China's clinical diagnostics sector, and we remain firmly optimistic about this future development trajectory. Kalupu boasts the most premier clinical mass spectrometry team in China, combining source innovation with strong commercialization capabilities. We are confident in the company's future growth and look forward to its continued pioneering efforts to drive the development of China's precision medicine industry."

Established in 2004, Chongqing Yufu Asset Management Group Co., Ltd. (hereinafter referred to as “Yufu”) is the first local state-owned wholly funded comprehensive asset management and operation company in China, approved by the Chongqing Municipal People’s Government. It is a major shareholder of nine listed companies, including Chongqing Rural Commercial Bank, Southwest Securities, and Chuanyi Automation. As a state-owned capital operating company, Yufu focuses on leveraging its “three major platforms”: a market-oriented operation platform for state-owned capital, a leading investment platform for strategic emerging industries, and a specialized restructuring platform for state-owned enterprise reform. It conducts capital investment and operations with a focus on four key areas: technological innovation, strategic emerging industries, modern finance, and science and technology parks.